Estrella Immunopharma Adds Fifth Site for Phase I/II EB103 Trial in B — Cell Non — Hodgkin’s Lymphoma

Estrella Immunopharma activated Intermountain Health LDS Hospital as the fifth site for its Phase I/II STARLIGHT-1 trial of EB103. The Salt Lake City hospital is expected to begin screening and enrolling patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma following site initiation. The ongoing expansion phase evaluates safety and efficacy, with results expected to inform a future pivotal trial strategy. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Estrella Immunopharma Inc. published the original content used to generate this news brief via (Ref. ID: 20261014129108) on October 14, 2026, and is solely responsible for the information contained therein. (C)